ArticleBlood2014

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

David H McDermott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.